In March 2020, "Coronavirus Disease 2019" (COVID-19) infection outbreak has been declared a pandemic by the World Health Organization, and until now, there are no proven drugs for the treatment of "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" infection; therefore affected symptomatic patients are treated with drugs already used for other infections1 such as hydroxychloroquine (HCQ) or chloroquine, administered alone or in combination with other medications
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency
Sgherza N.;Grasso S.;Musto P.
2020-01-01
Abstract
In March 2020, "Coronavirus Disease 2019" (COVID-19) infection outbreak has been declared a pandemic by the World Health Organization, and until now, there are no proven drugs for the treatment of "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" infection; therefore affected symptomatic patients are treated with drugs already used for other infections1 such as hydroxychloroquine (HCQ) or chloroquine, administered alone or in combination with other medicationsFile in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
